Session IX: Rectal Cancer
SESSION IX WEBCAST (with Slides - needs a registration)
Short Oral-37: Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer (EPOC 1)
The authors conclude that promising pCR rates of 30% and 60%, with mild toxicities, were shown in MSS and MSI-H LARC pts treated with nivolumab plus radical surgery after CRT. PD-L1 expression and elevated CD8ETreg ratio might be better predictors of pCR. Higher pCR rate suggested VOLTAGE regimen can be the candidate therapy for the future non-surgical approach.